BridgeBio Pharma (BBIO) 2025 Conference September 04, 2025 02:10 PM ET Company ParticipantsJosh Schimmer - Managing DirectorChinmay Shukla - SVP - Strategic Finance & IRChristine Siu - CEO - ML Bio SolutionsAnanth Sridhar - COOJosh SchimmerAll right, we're ready to get started. Welcome, everyone. I'm Josh Shummer from the Kantar Biotech Equity Research Team. Very pleased to introduce some of the management team from BridgeBio Pharma. We have Christine Xu, CEO of ML Bio Solutions. That's the limb-girdle musc ...

Group 1 - The article expresses a beneficial long position in the shares of ASND, indicating a positive outlook on the company's stock performance [1] - The author emphasizes that the opinions presented are personal and not influenced by any business relationships with the mentioned companies [1] - There is a clear distinction made that the commentary does not constitute personalized investment advice, urging readers to conduct their own due diligence [2] Group 2 - The article highlights that past performance is not indicative of future results, which is a common disclaimer in investment discussions [3] - It is noted that the views expressed may not reflect those of Seeking Alpha as a whole, indicating a diversity of opinions among analysts [3] - The article clarifies that Seeking Alpha does not act as a licensed securities dealer or investment adviser, reinforcing the need for independent research by investors [3]